Skip to Main Content

Paper Details

Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma.
Clin Cancer Res
3
2023
CIN, DNA-PK, DNA-PKcs, Doxorubicin, LMS, Leiomyosarcoma, PRKDC, RB1, RPA2, TP53, doxorubicin, genome, homologous recombination deficiency, mouse, mouse models, patient, patient-derived LMS cell lines, peposertib, sarcoma
Author NameAffiliation
Glenn S CowleyBroad Institute of Harvard and MIT
Peter J ParkHarvard Medical School
Peter J ParkHarvard Medical School
  • 1 - 3

Datasets

Release 1.2